-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although bone is the most common site of breast cancer metastasis, standard imaging methods have great limitations in identifying bone metastases and evaluating treatment response.
Although bone is the most common site of breast cancer metastasis, standard imaging methods have great limitations in identifying bone metastases and evaluating treatment response.
Recently, the use of whole-body MRI and diffusion-weighted sequence as a method for evaluating bone malignancies has become more and more accepted.
Retrospective data shows that whole-body MRI often reveals disease parts that are not obvious on CT images, and more than one-third of the cases only see evidence on whole-body MRI, so that changes can be made (15).
Recently, a study published in the journal Radiology explored whether whole-body MRI showed progressive disease (PD) earlier than CT and bone imaging in MBC with simple bone metastasis, providing an early, sensitive and specific clinical approach Higher imaging methods for evaluating MBC bone metastases.
Systemic Anti-tumor Therapy (SACT)
A total of 45 subjects (average age 60 years ± 13 years [standard deviation]; all females) were included in this study.
Of the 33 patients who showed PD on imaging, 67% (22) showed PD only on whole body MRI, 33% (11 showed PD on both CT and whole body MRI; no subjects showed PD only on CT images
Figure 36-year-old female, pathologically confirmed as grade 3 invasive ductal carcinoma with estrogen receptor positive and human epidermal growth factor receptor 2 negative.
2
This study shows that in most patients with breast cancer with simple bone metastases, whole-body MRI can identify progressive disease (PD) before CT.
This study shows that in most patients with breast cancer with simple bone metastases, whole-body MRI can identify progressive disease (PD) before CT.
Original source:
Michael Kosmin , Anwar R Padhani , Andrew Gogbashian , et al.
Michael Kosmin , Anwar R Padhani , Andrew Gogbashian , et al.
Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone .
DOI: org/10.
1148/radiol.
2020192683">10.
1148/radiol.
2020192683 10.
1148/radiol.
2020192683 Leave a message here
